NOVEL DRUG DELIVERY SYSTEMS IN CONTROLLED-RELEASE TABLETS: CURRENT TRENDS AND FUTURE PROSPECTS

Jyoti Gupta[1], Hans Raj[1]*, Saurav[1]

[1]IEC School of Pharmacy, IEC University Baddi, Solan-174103, Himachal Pradesh, India.

Corresponding author:

**Hans Raj*

**IEC School of Pharmacy, IEC University Baddi, Solan-174103, Himachal Pradesh, India.*

hchauhan513@gmail.com

Abstract: Recent years have seen a significant uptick in the amount of focus placed on controlled-release tablets within the pharmaceutical business. This may be attributed to the fact that these tablets are able to provide sustained drug release, improve patient compliance, and enhance therapeutic outcomes. This article provides an overview of the current status of innovative drug delivery technologies and analyses the possible applications of these systems in controlled-release tablet formulations. It examines a wide variety of approaches, instruments, and formulations that are used to achieve controlled medicine release, highlighting the advantages and limitations associated with each of these approaches. In addition to this, the research investigates potential remedies for the issues that arose throughout the process of developing these systems. The primary purpose of this study is to offer a comprehensive overview of the many controlled-release tablet technologies that are now available, with the end goal of paving the way for additional developments in the field of drug delivery.

Keyword: Controlled-release tablets; Novel drug delivery systems; Sustained drug release; Patient compliance; Therapeutic efficacy; Future prospects

1. INTRODUCTION:

Background and Significance of Controlled-Release Tablets:

Pharmaceutical formulations known as controlled-release tablets, often referred to as sustained-release or extended-release tablets, are created to release the active medication ingredient over a prolonged period of time at a regulated pace [1]. Conventional immediate- release formulations may cause drug concentration changes,

possible adverse effects, and decreased patient compliance since they release the medicine quickly after delivery. Controlled-release tablets, on the other hand, provide a number of benefits, including as maintaining therapeutic drug levels, lowering the frequency of dose, increasing patient convenience, and improving therapeutic results [2].

The creation of controlled-release pills has transformed the pharmaceutical sector and made itpossible to address a variety of medical diseases more effectively and safely [3]. These formulations have been effectively used, among other things, in the treatment of mental illnesses, chronic diseases, and pain management. Better effectiveness, less toxicity, and minimal side effects are all made possible by the careful regulation of drug release kinetics, which also improves the quality of life for patients [4].

Table 1: Comparison of Different Controlled-Release Tablet Technologies

Technology	Mechanism	Advantages	Limitations
Matrix Systems	Diffusion	Simple manufacturing process	Limited control over release kinetics
Osmotic Pumps	Osmosis	Precise and predictable release	Complex manufacturing process
Reservoir Systems	Diffusion/Erosion	Versatile for various drugs	Potential for burst release
Ion-Exchange Systems	Ion exchange	High drug-loading capacity	Risk of drug-resin interactions
Microencapsulation	Diffusion/Dissolution	Improved drug stability	Complex manufacturing process
Nanoparticle-based	Diffusion/Degradation	Targeted drug delivery	Regulatory challenges for approval
Lipid-based	Diffusion/Degradation	Enhanced drug solubility	Sensitivity to storage conditions

Rationale for Employing Novel Drug Delivery Systems:

Although traditional controlled-release formulations have shown to be successful in many situations, there is still a need for innovative drug delivery strategies to get around certain

drawbacks [5]. With the potential to target certain tissues or cells, fine-tune drug release patterns,and increase bioavailability, novel drug delivery systems provide chances to further enhance treatment [6]. The following justifies the use of innovative medication delivery techniques in controlled-release tablets:

a) Tailored release profiles: Different illnesses and treatments could call for different release characteristics. To suit certain therapeutic requirements, such as pulsatile release, circadian rhythms, or disease-dependent release patterns, novel delivery methods enable customisation [7].

b) Targeted drug delivery: Targeted drug delivery may reduce systemic exposure and increase therapeutic effectiveness for certain medications since they have particular target areas in the body. With the possibility for site-specific medication release, novel technologies may minimise side effects [8].

c) Enhanced patient adherence: A key healthcare concern is drug non-adherence. Improvedpatient adherence to treatment programmes may result from the use of novel drug delivery methods that decrease dose frequency or increase convenience [9].

d) Reduced side effects: Due to their quick release or high peak concentrations, certain medicines may have undesirable side effects. By keeping medication levels within a therapeuticrange that is both safe and effective, controlled-release devices may lessen the severity of theseadverse effects [10].

e) Improved safety and compliance: Novel delivery technologies that guarantee constant drug exposure and precise dosage may increase safety for medications with limited therapeuticwindows or complicated dosing regimens [11].

Table 2: Advantages and Limitations of Novel Drug Delivery Systems

Aspect	Advantages	Limitations
Improved Patient Compliance	Convenient dosing regimens	Complexity may lead to resistance by patients
Reduced Dosing Frequency	Improved adherence and treatment outcomes	Development costs for less frequent dosing
Enhanced Bioavailability	Predictable pharmacokinetics and efficacy	Potential interactions with delivery materials
Reduced Side Effects	Minimized off-target effects and systemic toxicity	Safety concerns of new delivery systems
Manufacturing Challenges	Scalability for commercial production	Increased manufacturing complexities and costs

Objectives of the Review:

The following are the main goals of this review:

a. to provide a general review of the newest developments and trends in controlled-releasetablet medication delivery.
b. to talk about the many methods, tools, and formulations used to accomplish controlledmedication release and their respective advantages.
c. to draw attention to the benefits and drawbacks of innovative medication delivery technologies in comparison to traditional formulations.
d. to investigate the difficulties encountered in the design and production of controlled- release tablets, as well as possible solutions.
e. to evaluate the possibilities for the future and new developments in the area of controlled-release tablet technologies, such as sustainable drug delivery systems, digitalhealth integration, and customised medicine [12].

By fulfilling these goals, this study hopes to further knowledge of controlled-release tablet technologies and provide insightful information to researchers, pharmaceutical companies, and medical professionals. Additionally, it aims to encourage additional study and innovation in the area, eventually enhancing patient outcomes and the state of drug delivery generally in contemporary medicine [13].

2. Current Approaches in Controlled-Release Tablet Formulations

Matrix Systems: One of the oldest and most popular methods for creating controlled-release tablet formulations is the matrix system. This method evenly distributes the medicationacross an inert matrix made of hydrophilic or hydrophobic polymers.

The medication diffuses through the matrix when the tablet comes into touch with bodily fluids, resulting in a gradual continuous release of the drug over time. The solubility of the medicine and the characteristics of the polymer matrix essentially determine the release rate [14].

Advantages:

- Straightforward manufacturing process.
- Cheaper than some other technologies.
- Suitable for a variety of pharmaceutical substances [15].

Limitations:

- Little control over the kinetics of medication release.
- For highly water-soluble medicines, burst release may occur during the first phase.
- May not be appropriate for medications whose solubility is pH-dependent [16].

Osmotic Pumps: Osmotic pressure is used by osmotic pump systems to regulate medication release. A semi-permeable membrane encircles the medication core in the tablet. Water seeps through the membrane of the tablet when it comes into touch with aqueous medium, increasing the pressure within the tablet. The medication solution or suspension is compelled to be discharged via a tiny hole at a regulated pace as a result of this pressure [17].

Advantages:

- Medication release kinetics that are exact and predictable.
- Little impact of physiological elements on drug release, such as pH and enzymes.
- Suited to medications with constrained therapeutic windows [18].

Limitations:

- Manufacturing procedure that is complex.
- Drugs having a low water solubility have a limited usage.
- Dumping of doses is a possibility should the delivery aperture get clogged [19].

Reservoir Systems: A membrane that controls flow rates surrounds a medication reservoir in reservoir systems. The drug formulation, which may be in the form of a solution, suspension, or solid dispersion, is contained in the drug reservoir [20]. Drug release is regulated by the rate- controlling membrane via diffusion or erosion processes. Through membrane holes or channels, the medication is discharged from the reservoir [21].

Advantages:

- Flexible mechanism that supports different medication compositions.
- Compared to matrix systems, better control over release rates.
- Both hydrophilic and hydrophobic medicines are suitable [22].

Limitations:

- Possibility of burst release, particularly if the drug reservoir is not filled evenly.
- The possibility of dosage dumping if the membrane is torn or damaged.
- Production costs may rise as a result of manufacturing complexity [23].

Ion-Exchange Systems: Ion-exchange resins are used in ion-exchange systems to regulate medication release [24]. The medication is adsorbed onto the resin, and the ion exchange betweenthe drug and the environment affects how quickly it is released. The release rate may be influenced by various ions, allowing the drug release to be modulated over time [25].

Advantages:

- High capacity for loading drugs.
- Decreased chance of dosage dumping.
- Possibility of release patterns that are activated by ions or by pH [26].

Limitations:

- Certain medications with certain chemical properties have a limited application.
- Drug stability may be impacted by drug-resin interactions.
- Possibility of release rates varying from batch to batch [27].

Microencapsulation: Drug particles are enclosed in a barrier during microencapsulation, creating microspheres or microcapsules [28]. The medicine diffusing through the coating or the coated material dissolving regulates the rate of release [29].

Advantages:

- Enhances stability and safeguards the medication from deterioration.
- Allows for customised medication targeting and release rates.

- Suitable for oral and injectable delivery methods, among others [30].

Limitations:

- Manufacturing procedure that is complex.
- If the coating is not uniform, there may be a danger of burst release.
- Creating a continuous zero-order release profile is challenging [31].

Nanoparticle-Based Systems: Drug molecules are transported by nanoparticles in systemsbased on them. Lipids, polymers, or metals are just a few of the components that may be used

to create these nanoparticles. The medicine is either adsorbed on the surface or enclosed insidethe nanoparticles, and the nanoparticle characteristics regulate the release rate [32].

Advantages:

- Improved medication stability and defence.
- Enhanced medication bioavailability and solubility.
- Possibility of site-specific medication release and tailored drug delivery [33].

Limitations:

- Regulatory difficulties in the approval of drugs based on nanoparticles.
- Limited knowledge on long-term toxicity and safety.
- Scalability for commercial manufacturing and complex synthesis [34].

Lipid-Based Delivery Systems: Drugs are delivered via lipid carriers as liposomes, micelles, or solid lipid nanoparticles in lipid-based delivery systems. Hydrophobic medicines may be trapped in or solubilized by lipid carriers, increasing their bioavailability and regulatingdrug release [35].

Advantages:

- Enhanced medication bioavailability and solubility.
- Reduced first-pass metabolism of medicines taken orally.
- Possibility of regulated release and focused distribution [36].

Limitations:

- Drug instability and lipid degradation risk.
- Difficulties in establishing formulation homogeneity.
- High sensitivity to temperature and storage conditions [37].

Other Emerging Technologies: Other cutting-edge technologies are being investigated forcontrolled-release tablet formulations [38], such as:

- Stimuli-responsive polymers and hydrogels.
- Techniques for delivering drugs that use magnets.
- 3D printing for custom drug formulations.
- Wearable and implantable medication delivery systems [39].

In the area of controlled-release medication delivery, these cutting-edge technologies continueto be the subject of intensive research and development because they have special benefits [40].

Overall, the ongoing investigation of these many strategies and technologies highlights the pharmaceutical industry's dedication to boosting therapeutic effectiveness and optimising drugdelivery to better patient outcomes. The selection of a particular strategy is based on the characteristics of the medication, the desired release profile, and the intended therapeutic use. Each method has advantages and disadvantages [41].

3. Technologies Enhancing Controlled Drug Release:

pH-Sensitive Systems: Drug release at certain areas inside the body may be triggered using pH-sensitive drug delivery devices. These systems often use coatings or polymers that are pH-responsive and display distinct physicochemical characteristics at various pH levels. Drug release is enhanced in acidic settings, such as the stomach or inflammatory tissues, whereas it is slowed down or stopped in neutral or alkaline conditions [42].

Applications:

- Targeted gastrointestinal tract delivery.
- Release that is localised to tumours or inflammatory tissues [43].

Advantages:

- Exact medication release at certain pH locations.
- Less negative effects in tissues that are healthy.
- Potential for medications with pH-dependent solubility to be taken orally [44].

Limitations:

- Individual differences in pH levels.
- Possible interactions between drugs and pH-sensitive polymers [45].

Temperature-Responsive Systems: Drug release is regulated by temperature variations in temperature-responsive drug delivery devices [46]. These systems use thermosensitive polymers, which change their phase in response to temperature changes. The solubility or permeability of the polymer varies at certain temperatures, resulting in controlled medication release [47].

Applications:

- Regionalized medication release in hot areas (e.g., tumors).
- Delivery to regions where body temperatures differ [48].

Advantages:

- Release on demand brought on by variations in temperature.
- Non-intrusive and rather simple to apply [49].

Limitations:

- It's possible that temperature changes don't always correspond to the intended areas.
- Possibility of hazardous polymers that are temperature-sensitive [50].

Enzyme-Triggered Release: Drug release is regulated by enzymes found in certain tissuesor disorders in enzyme-triggered drug delivery systems [51]. These systems often use polymers or drug carriers that are prone to enzymatic degradation. Enzymes cleave the carriers when they reach the intended environment, releasing the medication [52].

Applications:

- Medication release at a particular site in tissues with high enzyme activity.
- Delivery to specific tissues where illnesses like cancer are present [53].

Advantages:

- Very targeted and picky medication release.
- Lowered toxicity and off-target effects to a minimum [54].

Limitations:

- Individual differences in enzyme levels.
- Possibility of carrier deterioration before reaching the target location [55].

Targeted Drug Delivery: The goal of targeted drug delivery systems is to deliver medications just to the site of action that is desired, limiting exposure to tissues that are not thetarget [56]. The use of ligand-receptor interactions, antibody-drug conjugates, and surfacemodification with particular ligands are only a few of the targeted techniques used [57].

Applications:

- Delivery to certain cell types, inflammatory regions, or tumours on-site.
- Decreased systemic side effects and increased medication effectiveness [58].

Advantages:

- Better therapeutic index and effectiveness.
- A target location with higher medication concentrations [59].

Limitations:

- Finding and validating appropriate targeted ligands.
- Potential difficulties with cost and large-scale manufacturing [60].

Stimuli-Responsive Materials: Drug release is triggered by external stimuli like light, magnetic fields, ultrasound, or electric fields in stimuli-responsive drug delivery systems. These techniques often include adding stimuli-responsive components to medication carriers or coatings [61].

Applications:

- Localised medication release that is regulated remotely.
- Externally-triggered on-demand release [62].

Advantages:

- Precise control over the release of drugs in space and time.
- Possibility of individualised and non-invasive medication delivery [63].

Limitations:

- It's possible that external impulses don't always reach deep tissues.
- A dearth of appropriate stimuli-responsive materials [64].

By using these technologies, controlled medication release may be adapted to meet unique therapeutic needs and get around problems with traditional drug delivery methods [65]. For optimising medication regimens and enhancing patient outcomes, the ongoing developments in these fields offer enormous potential. To fully realise the promise of these technologies and transform them into therapeutic applications, more research and development are necessary [66].

4. Advantages and Limitations of Novel Drug Delivery Systems:

Improved Patient Compliance:

Advantages:

- With the use of simple dosage regimes like once-daily or less frequent dosing, noveldrug delivery systems may help patients adhere to treatment programmes more closely.
- Less frequent dosage may result in fewer missed doses, guaranteeing more constantmedication exposure and improving the efficacy of treatment.
- Patient satisfaction may be increased by using patient-friendly administration methodslike transdermal patches or oral controlled-release formulations [67].

Limitations:

- Patients may oppose or be reluctant to embrace new treatment approaches if certainnewer delivery systems are difficult or foreign to them.

- Patients can have trouble understanding correct administration or have trouble usingcertain delivery devices [68].

Reduced Dosing Frequency:

Advantages:

- Better patient compliance may result from less frequent administration, especially fordrugs with stringent dose schedules.
- The risk of dosage mistakes may be reduced with decreased frequency, enhancingpharmaceutical safety.
- Better treatment adherence and long-term results may result from increased patientconvenience [69].

Limitations:

- Drugs designed for prolonged release or less frequent dosage may need specificmanufacturing techniques, which may raise the cost of manufacture.
- Some medications may find it difficult to maintain regular drug release over prolongeddurations, which might have an impact on therapeutic effectiveness [70].

Enhanced Bioavailability and Therapeutic Efficacy:

Advantages:

- Innovative drug delivery methods may enhance drug solubility, stability, and absorption, increasing bioavailability and enhancing pharmacokinetic predictability.
- By ensuring that medication concentrations stay within the therapeutic range, controlled-release devices may maximise therapeutic effectiveness and lower the danger of both under- and overdose.
- By concentrating the medicine at precise locations of action, targeted drug delivery devices may enhance localised therapy while minimising systemic negative effects [71].

Limitations:

- It may be more expensive to create innovative medication delivery systems since theycall for more research and funding.
- Drug performance repeatability and consistency may be impacted by the complexityand unpredictability of the formulation [72].

Potential Side Effects and Safety Concerns:

Advantages:

- By keeping medication concentrations within the therapeutic window, controlled- release systems may help reduce certain adverse effects linked to formulations for immediate release.
- Improved safety profiles may result from targeted medication administration, which can lessen off-target effects and lower total systemic exposure [73].

Limitations:

- The introduction of novel drug delivery methods may raise fresh safety issues relatingto the substances used, the processes of release, or bodily interactions.
- Some people may have negative side effects or allergies to the medication deliverysystem's components [74].

Manufacturing Challenges and Cost Implications:

Advantages:

- As production quantities rise, scalability of manufacturing procedures for innovativedrug delivery systems may result in better cost-effectiveness over time.
- More dependable and consistent pharmaceutical goods may be produced via efficientproduction processes [75].

Limitations:

- The creation and use of innovative drug delivery systems may need specialised tools and knowledge, raising the difficulty and expense of manufacture.

- Drug affordability and accessibility may be impacted by higher production costs that are transferred to patients or healthcare systems [76].

Numerous benefits of novel drug delivery systems include increased patient compliance, higher therapeutic results, and decreased dose frequency. Some of the drawbacks of traditional medication formulations, including inconsistent drug release, low bioavailability, and frequentdosing, may be addressed by these methods. But they also present difficulties, such assignificant financial ramifications, difficult production procedures, and safety issues. For these novel technologies to be implemented and commercialised successfully, a balance between their benefits and drawbacks must be struck [77].

5. Challenges in Development and Manufacturing:

Regulatory Considerations: Novel medication delivery system advancements often bring new regulatory difficulties. To authorise and market new medicinal products, regulatory bodiesdemand extensive data on safety, effectiveness, and quality [78]. Among the obstacles in this areaare:

- **Lack of established guidelines:** Existing regulatory frameworks may not perfectly match novel drug delivery technologies, creating uncertainty in the approval process [79].
- **Demonstrating equivalence:** Due to variations in release kinetics, demonstrating bioequivalence for generic versions of controlled-release medications might be more difficult [80].
- **Complex approval pathways:** There may be additional or altered regulatory requirements for certain sophisticated delivery methods, which may lengthen thelicencing process [81].

To overcome these obstacles, it is necessary to work closely with regulatory agencies, participate in talks early on, and carefully record the data demonstrating the security and effectiveness of the unique drug delivery method [82].

Stability and Shelf-Life Issues: For pharmacological items to remain effective and safe over their shelf lives, stability is essential [83]. Among the obstacles in this area are:

- Extended-release durations may cause active pharmaceutical ingredients

(APIs) todegrade.

- interactions between the components of the delivery system and the medicine that mighthave an impact on drug stability.
- Some delivery methods are sensitive to the environment, which makes storage andtransit difficult [84].

In order to address stability difficulties, rigorous excipient selection, strong packaging methods, and comprehensive stability testing under various circumstances are needed [85].

Scale-Up and Manufacturing Complexities: Significant obstacles must be overcome in order to transition a promising innovative drug delivery method from laboratory to commercialmanufacture, including: [86]

- Ensuring consistency and repeatability while scaling up.
- Deciding on appropriate equipment and manufacturing processes for large-scale production.
- Overcoming technological obstacles, such as process optimization and yield enhancement, that may arise during scale-up [87].

Effective scale-up requires strong cooperation between formulation scientists and manufacturing specialists as well as early consideration of manufacturing issues during the research stage [88].

Quality Control and Assurance: For patient safety and product effectiveness, it is essential to maintain consistent product quality [89]. Among the difficulties in quality assurance and control are:

- Ensuring constant medication release characteristics amongst various batches.
- Creating trustworthy analytical techniques for evaluating the medication deliverysystem's essential quality characteristics.
- Addressing possible batch-to-batch variance brought on by differences in raw ingredients or production methods [90].

To offer dependable and secure medicinal products to patients, extensive in-process

testing, effective quality assurance systems, and implementation of complete quality control procedures are necessary.

A multidisciplinary strategy comprising formulation scientists, engineers, regulatory experts, and quality control professionals is required to properly handle these difficulties. The development and commercialization of innovative drug delivery systems with enhanced therapeutic results and patient benefits may be accelerated by collaboration between academics, industry, and regulatory agencies, which can also stimulate innovation and expediteregulatory routes [91].

6. Future Prospects and Emerging Trends in Drug Delivery:

Personalized Medicine and Individualized Dosing: Pharmacogenomics and personalised medicine developments are changing the way that drugs are delivered. Based on a patient's genetic composition, lifestyle, and other characteristics, personalised medicine tries to customise therapies for specific individuals. By offering personalised dose regimens, targeted administration, and controlled release profiles tailored to a patient's requirements, drug delivery systems may play a significant role in improving treatment. This strategy may boost patient adherence, reduce side effects, and improve treatment results [92].

Integration of Digital Health Technologies: An emerging concept that has considerable potential for enhancing patient outcomes and treatment monitoring is the integration of digital health technology with medication delivery systems. Smart drug delivery tools may gather real- time information on medicine use, adherence, and patient reactions. Examples include linked inhalers, injectors, and patches [93]. This information may be sent to healthcare practitioners via

cloud-based systems, allowing for remote monitoring, customised treatments, and prompt treatment plan modifications. Digital health technologies improve patient participation and make it possible to control diseases more successfully [94].

Combination Therapies and Polypharmacy Management: Combination therapy and polypharmacy are becoming increasingly common as our knowledge of illnesses and therapeutic approaches advances [95]. The simultaneous distribution of many medications with various release kinetics is made possible by novel drug delivery systems, improving therapeuticeffectiveness and streamlining patient dosage regimes.

By lowering dose frequency anddecreasing medication interactions, controlled-release formulations may also be very helpful in managing polypharmacy and improving patient compliance and treatment results [96].

Advancements in Nanotechnology and Biotechnology: Innovations in medication delivery are being driven by nanotechnology and biotechnology. Targeted distribution, greater drug stability, and increased bioavailability are all features of nanoparticle-based delivery systems including liposomes and polymeric nanoparticles [97]. With the use of these technologies, medications may be delivered to certain tissues or cells, including those within the blood-brain barrier, creating new opportunities for the treatment of cancer and neurological illnesses. Additionally, innovative drug delivery methods may be paired with advancements in biotechnology, such as gene and cell treatments, to produce precise and controlled release of therapeutic molecules [98].

Sustainable and Eco-Friendly Drug Delivery Systems: Sustainable and eco-friendly medicine delivery technologies are gaining popularity as environmental awareness grows [99]. Environmentally friendly medication carriers are being developed using biodegradable and biocompatible polymers. Additionally, the utilisation of green synthesis technologies and waste reduction in industrial processes is becoming a priority. Sustainable medication delivery methods not only lessen their negative effects on the environment, but they also help the general public's opinion of pharmaceuticals [100].

Table 3: Future Prospects and Emerging Trends in Drug Delivery

Trend	Description
Personalized Medicine and Individualized Dosing	Tailoring treatments based on genetic makeup and patient-specific factors.
Integration of Digital Health Technologies	Incorporating digital devices to monitor drug usage, adherence, and patient responses.

Combination Therapies and Polypharmacy Management	Simultaneous delivery of multiple drugs to enhance efficacy and simplify dosing.
Advancements in Nanotechnology and Biotechnology	Utilizing nanoparticles and biotechnological approaches for targeted delivery.
Sustainable and Eco-Friendly Drug Delivery Systems	Developing environmentally responsible drug carriers and green manufacturing methods.

Exciting innovations and game-changing technologies that promise to increase treatment accuracy, improve patient outcomes, and lessen the environmental impact of pharmaceuticals will shape the future of drug delivery [101]. At the vanguard of this transition are personalised medicine, digital health integration, combination medicines, nanotechnology, and sustainable drug delivery systems. These changes will change the way drugs are delivered, transforming medication administration and enhancing the effectiveness and safety of pharmacological therapies as they continue to develop [102].

CONCLUSION:

In conclusion, there has been a significant progress in the area of drug delivery, with new technology and creative strategies altering how pharmaceuticals are given out and enhancing patient results. Controlled-release drug delivery systems are a crucial field of study and development in pharmaceutical sciences because to its many benefits, which include increased patient compliance, increased therapeutic effectiveness, and decreased dose frequency.

The review has investigated a number of contemporary methods in the formulation of controlled-release tablets, including matrix systems, osmotic pumps, reservoir systems, ion- exchange systems, microencapsulation, nanoparticle-based systems, lipid-based delivery systems, and other cutting-edge technologies. Each strategy has advantages and disadvantages, emphasising the necessity for a method that is specifically matched to the therapeutic needs and medication qualities.

Additionally, innovations that improve controlled drug release, including pH-sensitive systems, temperature-responsive systems, enzyme-triggered release, targeted drug delivery, and stimuli- responsive materials, show enormous potential for attaining accurate and customised drug release patterns. These technologies provide the promise for tailored administration, reducing off-target effects and systemic toxicity while potentially improving therapeutic effectiveness and bioavailability.

To turn potential breakthroughs into marketable pharmaceutical products, it is necessary to efficiently handle hurdles in the development and manufacture of innovative drug delivery

systems, such as regulatory concerns, stability problems, scale-up difficulties, and quality control. In order to overcome these difficulties and hasten the commercialization of these sophisticated drug delivery systems, collaboration between regulatory authorities, industry, andacademia is essential.

Future possibilities and new developments in medication delivery have a significant impact onhow the pharmaceutical therapies environment will develop. Individualized dosage and personalised medicine are attempting to transform treatment modalities, and the use of digital health technology will improve patient participation and monitoring. Combination therapy and polypharmacy management aim to enhance treatment protocols, while advances in nano- and biotechnology provide alternatives for precise and targeted drug delivery.

Additionally, the increased focus on environmentally friendly and sustainable drug delivery methods underscores the need for responsible pharmaceutical development as well as expanding environmental consciousness. The pharmaceutical industry can usher in a new age of patient-centric, efficient, and sustainable drug delivery systems by tackling these trends and difficulties, thereby enhancing patient care and pushing the boundaries of contemporary medicine.

REFERENCES:

1. Bhowmik D, Bhanot R, Kumar KP. Extended Release Drug Delivery-An Effective Way of Novel Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018;10(4):233-44.
2. Laracuente ML, Marina HY, McHugh KJ. Zero-order drug delivery: State of the art andfuture prospects. Journal of Controlled Release. 2020 Nov 10;327:834-56.
3. Kim DY, Kadam A, Shinde S, Saratale RG, Patra J, Ghodake G. Recent developments in nanotechnology transforming the agricultural sector: a transition replete with opportunities. Journal of the Science of Food and Agriculture. 2018 Feb;98(3):849-64.

4. Mishra D, Hubenak JR, Mathur AB. Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2013 Dec;101(12):3646-60.
5. Park K. Controlled drug delivery systems: past forward and future back. Journal of Controlled Release. 2014 Sep 28;190:3-8.
6. Ruan S, Zhou Y, Jiang X, Gao H. Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Advanced Science. 2021 May;8(9):2004025.
7. CDC COVID-19 Response Team, CDC COVID-19 Response Team, CDC COVID-19Response Team, Burrer SL, de Perio MA, Hughes MM, Kuhar DT, Luckhaupt SE, McDaniel CJ, Porter RM, Silk B. Characteristics of health care personnel with COVID- 19—United States, February 12–April 9, 2020. Morbidity and Mortality Weekly Report. 2020 Apr 17;69(15):477-81.
8. Biharee A, Bhartiya S, Yadav A, Thareja S, Jain AK. Microsponges as Drug Delivery System: Past, Present, and Future Perspectives. Current Pharmaceutical Design. 2023 Apr 1;29(13):1026-45.
9. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert opinion on drug delivery. 2012 Oct 1;9(10):1263-71.
10. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Côté S, Shoichet BK. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 21;486(7403):361-7.
11. Villarruel Mendoza LA, Scilletta NA, Bellino MG, Desimone MF, Catalano PN. Recent advances in micro-electro-mechanical devices for controlled drug release applications. Frontiers in Bioengineering and Biotechnology. 2020 Jul 29;8:827.
12. Xu X, Awad A, Robles-Martinez P, Gaisford S, Goyanes A, Basit AW. Vat photopolymerization 3D printing for advanced drug delivery and medical

deviceapplications. Journal of Controlled Release. 2021 Jan 10;329:743-57.

13. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery.2021 Feb;20(2):101-24.
14. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. International journal of pharmaceutics. 2006 Feb 17;309(1-2):218-26.
15. Vulliet E, Cren-Olivé C, Grenier-Loustalot MF. Occurrence of pharmaceuticals and hormones in drinking water treated from surface waters. Environmental Chemistry Letters. 2011 Mar;9(1):103-14.
16. Monschke M, Kayser K, Wagner KG. Influence of particle size and drug load on amorphous solid dispersions containing pH-dependent soluble polymers and the weakbase ketoconazole. AAPS PharmSciTech. 2021 Jan;22:1-1.
17. Anandharamakrishnan C. Spray drying techniques for food ingredient encapsulation. John Wiley & Sons; 2015 Jul 23.
18. Schumacher D, Hackenberger CP, Leonhardt H, Helma J. Current status: site-specific antibody drug conjugates. Journal of clinical immunology. 2016 May;36:100-7.
19. Cazzola M, Cavalli F, Usmani OS, Rogliani P. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert opinion ondrug delivery. 2020 May 3;17(5):635-46.
20. Lugtu-Pe JA, Lin BY, Chen K, Ghaffari A, Kane A, Wu XY. Tailoring Release Profiles of BCS Class II Drugs Using Controlled Release Amorphous Solid Dispersion Beads with Membrane-Reservoir Design: Effect of Pore Former and Coating Levels. Molecular Pharmaceutics. 2021 Oct 20;18(11):4198-209.
21. Davoodi P, Lee LY, Xu Q, Sunil V, Sun Y, Soh S, Wang CH. Drug delivery systems for programmed and on-demand release. Advanced drug delivery reviews. 2018 Jul 1;132:104-38.
22. Roy A, Guha Ray P, Bose A, Dhara S, Pal S. pH-responsive copolymeric network gel using methacrylated β-Cyclodextrin for controlled codelivery of hydrophilic and hydrophobic drugs. ACS Applied Bio Materials. 2022 Jun 23;5(7):3530-43.
23. Alkan B, Vera DA, Ahmad M, Ahmad B, Harrison R. Complexity in

manufacturing systems and its measures: a literature review. European Journal of Industrial Engineering. 2018;12(1):116-50.

24. Jeong SH, Park K. Drug loading and release properties of ion-exchange resin complexes as a drug delivery matrix. International journal of pharmaceutics. 2008 Sep1;361(1-2):26-32.
25. De Robertis S, Bonferoni MC, Elviri L, Sandri G, Caramella C, Bettini R. Advances in oral controlled drug delivery: the role of drug–polymer and interpolymer non-covalentinteractions. Expert opinion on drug delivery. 2015 Mar 4;12(3):441-53.
26. Bundschuh M, Filser J, Lüderwald S, McKee MS, Metreveli G, Schaumann GE, Schulz R, Wagner S. Nanoparticles in the environment: where do we come from, where do wego to?. Environmental Sciences Europe. 2018 Dec;30(1):1-7.
27. Philip P, Meier K, Kern D, Goldmanns J, Stockmeier F, Bähr C, Büchs J. Systematic evaluation of characteristics of the membrane-based fed-batch shake flask. Microbial Cell Factories. 2017 Dec;16(1):1-7.
28. Singh MN, Hemant KS, Ram M, Shivakumar HG. Microencapsulation: A promising technique for controlled drug delivery. Research in pharmaceutical sciences. 2010 Jul;5(2):65.
29. Yadav G, Bansal M, Thakur N, Khare S, Khare P. Multilayer tablets and their drug release kinetic models for oral controlled drug delivery system. ME J Sci Res. 2013;16:782-95.
30. Song H, Fan Y, Zhang J, Cooper AM, Silver K, Li D, Li T, Ma E, Zhu KY, Zhang J. Contributions of dsRNases to differential RNAi efficiencies between the injection and oral delivery of dsRNA in Locusta migratoria. Pest management science. 2019 Jun;75(6):1707-17.
31. Laracuente ML, Marina HY, McHugh KJ. Zero-order drug delivery: State of the art andfuture prospects. Journal of Controlled Release. 2020 Nov 10;327:834-56.
32. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and surfaces B: biointerfaces. 2010 Jan 1;75(1):1-8.
33. Luo Y, Yang H, Zhou YF, Hu B. Dual and multi-targeted nanoparticles for site-

specific brain drug delivery. Journal of Controlled Release. 2020 Jan 10;317:195-215.

34. Safian MT, Umar K, Ibrahim MN. Synthesis and scalability of graphene and its derivatives: A journey towards sustainable and commercial material. Journal of CleanerProduction. 2021 Oct 10;318:128603.
35. Son GH, Lee BJ, Cho CW. Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles. Journal of Pharmaceutical Investigation. 2017 Jul;47:287-96.
36. O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nature reviews Molecular cell biology. 2020 Oct;21(10):585-606.
37. Lafrenière MA, Tandon V, Ainsworth C, Nouri K, Mondoux SE, Worster A, Kavsak PA. Storage conditions, sample integrity, interferences, and a decision tool for investigating unusual high-sensitivity cardiac troponin results. Clinical Biochemistry. 2023 May 1;115:67-76.
38. Wairkar S, Gaud R, Raghavan A. Multi-particulate systems: cutting-edge technology for controlled drug delivery. Recent patents on drug delivery & formulation. 2016 Dec1;10(3):184-91.
39. Kar A, Ahamad N, Dewani M, Awasthi L, Patil R, Banerjee R. Wearable and implantable devices for drug delivery: Applications and challenges. Biomaterials. 2022Apr 1;283:121435.
40. Chakraborty P, Das SS, Dey A, Chakraborty A, Bhattacharyya C, Kandimalla R, Mukherjee B, Gopalakrishnan AV, Singh SK, Kant S, Nand P. Quantum dots: The cutting-edge nanotheranostics in brain cancer management. Journal of ControlledRelease. 2022 Oct 1;350:698-715.
41. Auriemma G, Tommasino C, Falcone G, Esposito T, Sardo C, Aquino RP. Additive manufacturing strategies for personalized drug delivery systems and medical devices: fused filament fabrication and semi solid extrusion. Molecules. 2022 Apr 27;27(9):2784.
42. Kulkarni N, Jain P, Shindikar A, Suryawanshi P, Thorat N. Advances in the colon- targeted chitosan based multiunit drug delivery systems for the treatment of inflammatory bowel disease. Carbohydrate Polymers. 2022 Jul 15;288:119351.

43. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. Journal of controlledrelease. 2012 Apr 10;159(1):14-26.
44. Zhang L, Wu F, Lee SC, Zhao H, Zhang L. pH-dependent drug–drug interactions for weak base drugs: potential implications for new drug development. Clinical Pharmacology & Therapeutics. 2014 Aug;96(2):266-77.
45. Ofridam F, Tarhini M, Lebaz N, Gagnière É, Mangin D, Elaissari A. pH-sensitive polymers: Classification and some fine potential applications. Polymers for AdvancedTechnologies. 2021 Apr;32(4):1455-84.
46. Amoli-Diva M, Sadighi-Bonabi R, Pourghazi K. Switchable on/off drug release from gold nanoparticles-grafted dual light-and temperature-responsive hydrogel for controlled drug delivery. Materials Science and Engineering: C. 2017 Jul 1;76:242-8.
47. Movassaghian S, Merkel OM, Torchilin VP. Applications of polymer micelles for imaging and drug delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2015 Sep;7(5):691-707.
48. Lubkowska A, Szymański S, Chudecka M. Neonatal thermal response to childbirth: Vaginal delivery vs. caesarean section. Plos one. 2020 Dec 9;15(12):e0243453.
49. Caroux L, Consel C, Dupuy L, Sauzéon H. Verification of daily activities of older adults: a simple, non-intrusive, low-cost approach. InProceedings of the 16th international ACM SIGACCESS conference on Computers & accessibility 2014 Oct 20 (pp. 43-50).
50. Kim DH, Guo Y, Zhang Z, Procissi D, Nicolai J, Omary RA, Larson AC. Temperature- sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia. Advanced healthcare materials. 2014 May;3(5):714-24.
51. Cao Z, Li W, Liu R, Li X, Li H, Liu L, Chen Y, Lv C, Liu Y. pH-and enzyme-triggereddrug release as an important process in the design of anti-tumor drug delivery systems.Biomedicine & Pharmacotherapy. 2019 Oct 1;118:109340.
52. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert opinion on drug delivery. 2010 Apr 1;7(4):479-95.
53. Badar A, Pachera S, Ansari AS, Lohiya NK. Nano based drug delivery systems:

presentand future prospects. Nanomed Nanotechnol J. 2019;2(1):121.

54. Gao Y, Wu H, Wang Y, Liu X, Chen L, Li Q, Cui C, Liu X, Zhang J, Zhang Y. Single Cas9 nickase induced generation of NRAMP1 knockin cattle with reduced off-target effects. Genome biology. 2017 Dec;18(1):1-5.
55. Su Y, Xie Z, Kim GB, Dong C, Yang J. Design strategies and applications of circulating cell-mediated drug delivery systems. ACS biomaterials science & engineering. 2015 Apr 13;1(4):201-17.
56. Saha RN, Vasanthakumar S, Bende G, Snehalatha M. Nanoparticulate drug delivery systems for cancer chemotherapy. Molecular membrane biology. 2010 Oct 1;27(7):215-31.
57. Wang X, Liu Y, Fan X, Wang J, Ngai WS, Zhang H, Li J, Zhang G, Lin J, Chen PR. Copper-triggered bioorthogonal cleavage reactions for reversible protein and cell surface modifications. Journal of the American Chemical Society. 2019 Oct 3;141(43):17133-41.
58. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.Annals of the rheumatic diseases. 2010 Jan 1;69(01):20-8.
59. Heinrichs MT, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, Gogishvili S, Little BP, Bernheim A, Guarner J, Peloquin CA. Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical

    pharmacokinetic study. Journal of Antimicrobial Chemotherapy. 2018 Feb 1;73(2):477-83.
60. Buyel JF, Twyman RM, Fischer R. Very-large-scale production of antibodies in plants: The biologization of manufacturing. Biotechnology Advances. 2017 Jul 1;35(4):458- 65.
61. Hoffman AS. Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Advanced drug delivery reviews. 2013 Jan 1;65(1):10-6.
62. Kim J, Singh B, Shukla N, Lee J, Kim K, Park MH. On-Demand Drug-Delivery Platform Using Electrospun Nanofibers by Externally Triggered Glass Transition Switch. ACS Materials Letters. 2022 Oct 18;4(11):2252-60.
63. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim

G, Suksuwan W, Sungkanuparph S, Phuphuakrat A. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study.Clinical Microbiology and Infection. 2021 Feb 1;27(2):285-e1.

64. Du FS, Wang Y, Zhang R, Li ZC. Intelligent nucleic acid delivery systems based on stimuli-responsive polymers. Soft Matter. 2010;6(5):835-48.
65. Weaver CL, LaRosa JM, Luo X, Cui XT. Electrically controlled drug delivery from graphene oxide nanocomposite films. ACS nano. 2014 Feb 25;8(2):1834-43.
66. McNaughton D, Light J. The iPad and mobile technology revolution: Benefits and challenges for individuals who require augmentative and alternative communication. Augmentative and alternative communication. 2013 Jun 1;29(2):107-16.
67. Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Expert opinion on drug delivery. 2011 Nov 1;8(11):1521-9.
68. Lewis SL, Bucher L, Heitkemper MM, Harding MM, Kwong J, Roberts D. Medical- Surgical Nursing-E-Book: Assessment and Management of Clinical Problems, Single Volume. Elsevier Health Sciences; 2016 Sep 8.
69. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. Journal of the European Academy of Dermatology and Venereology. 2011 Jun;25:9-14.
70. Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. Journal of controlled release. 2012 Dec 10;164(2):192-204.
71. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery.2021 Feb;20(2):101-24.
72. National Academies of Sciences, Engineering, and Medicine. Reproducibility and replicability in science.
73. Sousa F, Dhaliwal HK, Gattacceca F, Sarmento B, Amiji MM. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. Journal of Controlled Release. 2019 Sep 10;309:37-47.

74. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New England journal of medicine. 2000 Dec 21;343(25):1833-8.
75. Srai JS, Kumar M, Graham G, Phillips W, Tooze J, Ford S, Beecher P, Raj B, GregoryM, Tiwari MK, Ravi B. Distributed manufacturing: scope, challenges and opportunities. International Journal of Production Research. 2016 Dec 1;54(23):6917- 35.
76. Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S, Roman J, Harbeck N, Eniu A. Enhancing global access to cancer medicines. CA: a cancer journal for clinicians. 2020 Mar;70(2):105-24.
77. Liu JK. The history of monoclonal antibody development–progress, remaining challenges and future innovations. Annals of medicine and surgery. 2014 Dec 1;3(4):113-6.
78. Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing–an overview. Vaccine. 2017 Jul 24;35(33):4064-71.
79. Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, Ferguson J, Garner S, Honig P, Hukkelhoven M, Lim JC. Adaptive licensing: taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics. 2012 Mar;91(3):426-37.
80. Shen J, Burgess DJ. In vitro–in vivo correlation for complex non-oral drug products: where do we stand?. Journal of controlled release. 2015 Dec 10;219:644-51.
81. Desai N. Challenges in development of nanoparticle-based therapeutics. The AAPS journal. 2012 Jun;14(2):282-95.
82. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC medicine. 2019 Dec;17:1- 9.
83. Szymańska E, Winnicka K. Stability of chitosan—a challenge for pharmaceutical and biomedical applications. Marine drugs. 2015 Apr 1;13(4):1819-46.

84. Qureshi F, Yusuf M, Khan MA, Ibrahim H, Ekeoma BC, Kamyab H, Rahman MM, Nadda AK, Chelliapan S. A State-of-The-Art Review on the Latest trends in Hydrogen production, storage, and transportation techniques. Fuel. 2023 May 15;340:127574.
85. González-González O, Ramirez IO, Ramirez BI, O'Connell P, Ballesteros MP, Torrado JJ, Serrano DR. Drug stability: ich versus accelerated predictive stability studies. Pharmaceutics. 2022 Oct 28;14(11):2324.
86. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced drug delivery reviews. 2017 Jan 1;108:25-38.
87. Kalista B, Shin H, Cho J, Jang A. Current development and future prospect review of freeze desalination. Desalination. 2018 Dec 1;447:167-81.
88. Kalaria DR, Parker K, Reynolds GK, Laru J. An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles. Drug Discovery Today. 2020 Mar 1;25(3):505-18.
89. Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion on Biological Therapy. 2018 Apr 3;18(4):369-79.
90. Miranda M, Cova T, Augusto C, Pais AA, Cardoso C, Vitorino C. Diving into Batch- to-Batch Variability of Topical Products-a Regulatory Bottleneck. Pharmaceutical Research. 2020 Nov;37:1-7.
91. Pearson AD, Weiner SL, Adamson PC, Karres D, Reaman G, Rousseau R, Blanc P, Norga K, Skolnik J, Kearns P, Scobie N. ACCELERATE–Five years accelerating cancer drug development for children and adolescents. European Journal of Cancer. 2022 May 1;166:145-64.
92. Aleksovski A, Dreu R, Gašperlin M, Planinšek O. Mini-tablets: a contemporary systemfor oral drug delivery in targeted patient groups. Expert opinion on drug delivery. 2015Jan 2;12(1):65-84.
93. Awad A, Trenfield SJ, Pollard TD, Ong JJ, Elbadawi M, McCoubrey LE, Goyanes A,Gaisford S, Basit AW. Connected healthcare: Improving patient care using digital healthtechnologies. Advanced Drug Delivery Reviews. 2021 Nov 1;178:113958.

94. Liu Y, Zhang L, Yang Y, Zhou L, Ren L, Wang F, Liu R, Pang Z, Deen MJ. A novel cloud-based framework for the elderly healthcare services using digital twin. IEEE access. 2019 Apr 11;7:49088-101.
95. Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology. Medicinal Research Reviews. 2021 Sep;41(5):2606-33.
96. Gooch N, Molokhia SA, Condie R, Burr RM, Archer B, Ambati BK, Wirostko B. Ocular drug delivery for glaucoma management. Pharmaceutics. 2012 Mar 8;4(1):197-211.
97. Wang Y, Xu X, Gu Y, Cheng Y, Cao F. Recent advance of nanoparticle-based topicaldrug delivery to the posterior segment of the eye. Expert opinion on drug delivery. 2018Jul 3;15(7):687-701.
98. Angell C, Xie S, Zhang L, Chen Y. DNA nanotechnology for precise control over drugdelivery and gene therapy. Small. 2016 Mar;12(9):1117-32.
99. Moshood TD, Nawanir G, Mahmud F, Mohamad F, Ahmad MH, AbdulGhani A. Sustainability of biodegradable plastics: New problem or solution to solve the global plastic pollution?. Current Research in Green and Sustainable Chemistry. 2022 Jan 1;5:100273.
100. Kümmerer K. The presence of pharmaceuticals in the environment due to human use–present knowledge and future challenges. Journal of environmental management. 2009 Jun 1;90(8):2354-66.
101. Kotta S, Nair A, Alsabeelah N. 3D printing technology in drug delivery: recentprogress and application. Current pharmaceutical design. 2018 Nov 1;24(42):5039-48.
102. Fenton OS, Olafson KN, Pillai PS, Mitchell MJ, Langer R. Advances in biomaterials for drug delivery. Advanced Materials. 2018 Jul;30(29):1705328.